We are live on ! Find out more
LPCN icon

Lipocine
LPCN

37 hedge funds and large institutions have $18.6M invested in Lipocine in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

0.34% less ownership

Funds ownership: 1.67% → 1.33% (-0.34%)

12% less funds holding

Funds holding: 42 → 37 (-5)

15% less capital invested

Capital invested by funds: $21.9M → $18.6M (-$3.37M)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

74% less call options, than puts

Call options by funds: $451K | Put options by funds: $1.72M

Holders
37
Holders Change
-5
Holders Change %
-11.9%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
11
Reduced
9
Closed
11
Calls
$451K
Puts
$1.72M
Net Calls
-$1.26M
Net Calls Change
-$1.86M

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$972K
2
DAM
DLD Asset Management
New York
+$934K
3
Deutsche Bank
Deutsche Bank
Germany
+$565K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$511K
5
PAWC
P.A.W. Capital
Connecticut
+$425K

Top Sellers

1
CAM
Cormorant Asset Management
Massachusetts
-$2.98M
2
RA
Royce & Associates
New York
-$1.43M
3
CC
Carlson Capital
Texas
-$425K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$353K
5
Goldman Sachs
Goldman Sachs
New York
-$300K
Name Holding Trade Value Shares
Change 		Change in
Stake
RA
1
Royce & Associates
New York
$3.35M -$1.43M -19,739 -28%
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.65M +$511K +7,071 +22%
CC
3
Carlson Capital
Texas
$1.99M -$425K -5,882 -17%
DAM
4
DLD Asset Management
New York
$1.59M +$934K +12,912 +121%
VMI
5
VHCP Management II
New York
$1.54M – – –
BlackRock
6
BlackRock
New York
$1.34M +$209K +2,891 +17%
Renaissance Technologies
7
Renaissance Technologies
New York
$908K +$972K +13,447 New
Millennium Management
8
Millennium Management
New York
$767K +$8.1K +112 +1%
Ameriprise
9
Ameriprise
Minnesota
$641K +$24.7K +341 +4%
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$634K -$353K -4,888 -34%
Deutsche Bank
11
Deutsche Bank
Germany
$606K +$565K +7,812 +663%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$414K – – –
PAWC
13
P.A.W. Capital
Connecticut
$397K +$425K +5,882 New
Federated Hermes
14
Federated Hermes
Pennsylvania
$340K -$10.3K -143 -3%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$193K – – –
California Public Employees Retirement System
16
California Public Employees Retirement System
California
$183K – – –
WVP
17
Worth Venture Partners
New Jersey
$171K +$84.9K +1,174 +86%
Northern Trust
18
Northern Trust
Illinois
$167K +$49K +678 +38%
KCM
19
Knoll Capital Management
Florida
$99K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$90K +$96.2K +1,330 New
PPA
21
Parametric Portfolio Associates
Washington
$69K -$3.76K -52 -5%
ARTA
22
A.R.T. Advisors
New York
$64K +$69.6K +963 New
State Street
23
State Street
Massachusetts
$63K – – –
VF
24
Virtu Financial
New York
$63K +$67.5K +934 New
ECM
25
Element Capital Management
New York
$44K -$296K -4,099 -86%
1
2

LPCN Hedge Fund Activity: Q3 2017 in Review

37 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2017, worth a combined $18.6M — down 15% from $21.9M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of LPCN and 6 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 11 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $972K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.98M sold.

  • 37 institutional investors held Lipocine (LPCN) as of Q3 2017, down from 42 in Q2 2017.
  • Funds reported $18.6M of Lipocine stock for Q3 2017, down 15% quarter-over-quarter.
  • 6 funds opened new Lipocine positions in Q3 2017 and 11 closed out, a net change of -5 holders.
  • The largest Lipocine buyer in Q3 2017 was Renaissance Technologies, an estimated $972K added.
  • The largest Lipocine seller in Q3 2017 was Cormorant Asset Management, an estimated $2.98M sold.

Based on aggregated 13F filings for Q3 2017.